Personalis Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025,...
What technical or competitive risks could affect the sustainability of the 59% test volume growth?
What is the expected impact of potential dilution from future equity issuances or convertible debt?
How have recent macro‑economic factors (e.g., reimbursement policy changes, healthcare spending trends) impacted the outlook?
18 days ago